Real-world efficacy and safety of donafenib-based therapies in patients with unresectable hepatocellular carcinoma: A retrospective study.

被引：0
|
作者：
Shang, Changzhen [1 ]
Luo, Xuan [1 ]
Zhong, Jinyi [1 ]
Zhang, Jianlong [1 ]
Li, Huilong [1 ]
Tan, Wenliang [1 ]
Lei, Zhang [1 ]
Chen, Yajin [1 ]
机构：
[1] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Hepatobiliary Surg, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16169
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of donafenib combined with anti-PD-1 antibodies for initially unresectable hepatocellular carcinoma (HCC): A retrospective real-world study.
    Liu, Sulai
    Zhou, Shuyi
    Song, Yinghui
    Liu, Jianming
    Guo, Chao
    Yang, Pingzhou
    Li, Ou
    Yi, Weimin
    Peng, Chuang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Efficacy and safety of TACE combined with ablation and regorafenib for unresectable hepatocellular carcinoma: A real-world study.
    Xiong, Yiqi
    Gao, WenFeng
    Long, Jiang
    Hu, CaiXia
    Yuan, ChunWang
    Sun, Yu
    Shi, QinSheng
    Sun, Bin
    Zhang, YingHua
    Cui, XiongWei
    Hao, MeiJun
    Li, Jianjun
    Zhang, Yonghong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] The efficacy and safety of lenvatinib for advanced hepatocellular carcinoma in China: A retrospective, real-world study.
    Yang, Xin-Rong
    Guo, De-Zhen
    Chen, Fei-Yu
    Fan, Jia
    Jian, Zhou
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Real-world registry of patients with unresectable hepatocellular carcinoma: The OREIOS study.
    Chan, Stephen Lam
    Ryu, Min-Hee
    Waked, Imam
    Shao, Yu Yun
    Tai, Wai Meng David
    Breder, Valeriy
    Alolayan, Ashwaq
    Ganguly, Sandip
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS618 - TPS618
  • [5] Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China
    Zhu, Yun
    Sun, Penghui
    Wang, Kunyuan
    Xiao, Shuzhe
    Cheng, Yanling
    Li, Xiangzhao
    Wang, Biao
    Li, Jiancong
    Yu, Wenxuan
    Cheng, Yang
    [J]. CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [6] Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China
    Yun Zhu
    Penghui Sun
    Kunyuan Wang
    Shuzhe Xiao
    Yanling Cheng
    Xiangzhao Li
    Biao Wang
    Jiancong Li
    Wenxuan Yu
    Yang Cheng
    [J]. Cancer Cell International, 21
  • [7] Efficacy and safety of transarterial therapy combined with donafenib plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A multicenter retrospective study.
    Shang, Changzhen
    Zhong, Jinyi
    Luo, Xuan
    Zhang, Bo
    Chen, Huanwei
    Wang, Fengjie
    Jiang, Xiaofeng
    Cao, Liangqi
    Shen, Shun-Li
    Chen, Yajin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Transarterial chemoembolization combined with donafenib or lenvatinib as first-line treatment for unresectable hepatocellular carcinoma: A single-center real-world retrospective study.
    Liu, Huan
    Huang, Mingsheng
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Safety and efficacy of lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC) in real-world practice in Korea
    Kang, W.
    Kim, J.
    Kim, S. U.
    Seo, Y-S.
    Kim, J.
    Kim, J-H.
    Park, S. Y.
    Baek, Y-H.
    Kim, K.
    Lee, H. L.
    Yoon, K. T.
    Kim, H.
    Cheong, J. Y.
    Hwang, J. S.
    Kim, J. H.
    Kim, K. M.
    Sung, P. S.
    Kim, J. J.
    Kim, D-Y.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S609 - S609
  • [10] Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan
    Shimozato, Naotaka
    Namisaki, Tadashi
    Okano, Akihiro
    Ohana, Masaya
    Kinoshita, Daisuke
    Kawasaki, Toshihiko
    Aihara, Yosuke
    Nakatani, Toshiya
    Kinoshita, Hiroki
    Ann, Tatsuichi
    Saito, Ko
    Yoshida, Motoyuki
    Yoshiji, Hitoshi
    [J]. ANTICANCER RESEARCH, 2022, 42 (01) : 173 - 183
12345